TY - JOUR
T1 - Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis
T2 - A multicenter placebo-controlled trial
AU - Spruance, Spotswood L.
AU - Stewart, Jeffery C.B.
AU - Freeman, Donna J.
AU - Brightman, Vernon J.
AU - Cox, Jack L.
AU - Wenerstrom, Gay
AU - McKeough, Mark B.
AU - Rowe, Nathaniel H.
N1 - Funding Information:
Received 24 April 1989; revised 29 August 1989. Presented in part at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1989, Houston. Each participant signed an Institutional Review Board-approved document of informed consent, and guidelines for human experimentation at each institution were followed. Supported in part bya grant from Research Medical, Inc. , Salt Lake City, and by grants RR-<>0064 and RR-01224, Division of Research Resources, National Institutes of Health. Reprints and correspondence: Dr. S. L. Spruance, Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132.
PY - 1990/2
Y1 - 1990/2
N2 - In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P =.01)and the mean healing time to loss of crust by 1.7 days (21%, P =.004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P =.OS) and the mean healing time to loss of crust by 3.3 days (3S%, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there wasa greater drug effect on the duration of pain (reduction by 2.6 days, 49%; P =.03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23%; P =.004). Adverse reactions to the medication were minimal.
AB - In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P =.01)and the mean healing time to loss of crust by 1.7 days (21%, P =.004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P =.OS) and the mean healing time to loss of crust by 3.3 days (3S%, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there wasa greater drug effect on the duration of pain (reduction by 2.6 days, 49%; P =.03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23%; P =.004). Adverse reactions to the medication were minimal.
UR - http://www.scopus.com/inward/record.url?scp=0025019789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025019789&partnerID=8YFLogxK
U2 - 10.1093/infdis/161.2.191
DO - 10.1093/infdis/161.2.191
M3 - Article
C2 - 2153736
AN - SCOPUS:0025019789
SN - 0022-1899
VL - 161
SP - 191
EP - 197
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -